Karyopharm and menarini group receive full marketing authorisation from the european commission for nexpovio® (selinexor) for the treatment of patients with multiple myeloma after at least one prior therapy

– based on results from phase 3 boston study, marketing authorisation expands multiple myeloma indication – – approval follows positive opinion by european committee for medicinal products for human use (chmp) in may 2022 – newton, mass. and florence, italy , july 21, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the menarini group ("menarini"), a privately-held, leading international pharmaceutical company, today announced that the european commission (ec) has granted marketing authorisation for nexpovio® (selinexor), a first-in-class, oral exportin 1 (xpo1) inhibitor, in combination with once-weekly bortezomib (velcade®) and low-dose dexamethasone (svd) for the treatment of adults with multiple myeloma who have received at least one prior therapy.
KPTI Ratings Summary
KPTI Quant Ranking